The global Neurological Biomarkers Market is expanding significantly due to the increasing prevalence of neurodegenerative disorders and growing demand for early disease diagnosis technologies. Neurological biomarkers are increasingly used to identify and monitor conditions such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and autism spectrum disorders. Advancements in molecular diagnostics, proteomics, genomics, and imaging technologies are supporting the development of highly sensitive neurological biomarkers. Pharmaceutical companies are also increasingly integrating biomarker-based approaches into clinical trials and drug development programs.

According to Fortune Business Insights, the global neurological biomarkers market was valued at USD 10.42 billion in 2025 and is projected to grow from USD 11.79 billion in 2026 to USD 31.54 billion by 2034, exhibiting a CAGR of 13.09% during the forecast period.

Why is the Neurological Biomarkers Market Growing?

The rising prevalence of neurodegenerative and neurological disorders is one of the primary factors driving the market. Increasing cases of Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and other neurological conditions are creating demand for technologies capable of supporting early diagnosis, disease monitoring, and treatment evaluation.

Neurological biomarkers can help healthcare professionals identify biological changes associated with disease progression and support more personalized treatment strategies. Growing investments in neuroscience research, precision medicine, and biomarker discovery are further contributing to market expansion.

Neurological biomarkers are increasingly used for:

• Alzheimer’s disease diagnosis and monitoring
• Parkinson’s disease research
• Multiple sclerosis monitoring
• Autism research
• Neurodegenerative disease detection
• Drug development
• Clinical trials
• Precision medicine
• Treatment-response monitoring
• Disease progression assessment

Key Market Trends Shaping Industry Growth

Rising Demand for Early Neurological Disease Diagnosis

The growing focus on early diagnosis is increasing demand for sensitive neurological biomarkers. Healthcare providers and research organizations are increasingly exploring biomarkers that can identify neurological disorders before severe symptoms develop.

Blood-based and cerebrospinal-fluid biomarkers are receiving increasing attention because they can support disease detection and monitoring while improving the efficiency of diagnostic workflows.